LumiThera Presents US LIGHTSITE III Trial Data Showing Improvement in Vision in Intermediate Dry...
WFMZ Eastern Pennsylvania and Western New Jersey· 6 days agoSEATTLE, June 22, 2022 /PRNewswire/ -- LumiThera Inc., a commercial stage medical device company...
2-Year Faricimab Results: 'Visual Gains With Fewer Injections'
Medscape· 2 days agoThe trials compared two dosing regimens of faricimab — including a personalized treatment interval...
Kinarus Therapeutics to host KOL event on Monday, June 27, to discuss therapies in wet Age-Related ...
Morningstar· 5 days agoKinarus Therapeutics to host KOL event on Monday, June 27, to discuss therapies in wet Age-Related Macular Degeneration and potential advantages of KIN001 ...
Morphology of en face Haller vessel and macular neovascularization at baseline and 3 months as...
Nature· 4 days agoThe inclusion criteria were age 50 years or older, treatment-naïve nAMD confirmed by multimodal retinal imaging (fluorescein angiography, indocyanine green angiography, and ...
Eom Pharmaceuticals files for possible $25M IPO, changing name from Intercellular
Seeking Alpha· 22 hours agoEom’s lead product, EOM613, is currently in Phase 1/2a testing in Brazil for the treatment of...
Apellis (APLS) Expands Deal for Targeted Complement Therapies
MSN News· 14 hours agoApellis Pharmaceuticals, Inc. APLS announced that it has expanded its existing research and...
EyePoint Pharmaceuticals Announces Election of Tony Adamis, M.D. to Board of Directors
Morningstar· 5 days agoDr. Adamis is a highly accomplished ophthalmology executive with more than 30 years of research and development experience in the biopharmaceutical industry. “Dr. Adamis is a pioneer in the ...
Cost of ranibizumab port delivery system for treating nAMD examined
Medical Xpress· 5 days agoFor patients with neovascular age-related macular degeneration (nAMD), ranibizumab with a port...
Adverum Biotechnologies Obtains EMA’s Priority Medicines Status For Chronic Eye Disorder Candidate -...
Benzinga· 4 days agoThe European Medicines Agency (EMA) has granted Priority Medicines (PRIME) designation to Adverum Biotechnologies’ ADVM lead drug ADVM-022 for the treatment of wet age-related ...
Kodiak Sciences Inc. (NASDAQ:KOD) Given Average Recommendation of “Hold” by Analysts
ETF DAILY NEWS· 4 days agoKodiak Sciences Inc. (NASDAQ:KOD – Get Rating) has earned a consensus recommendation of “Hold” from the nine research firms that are presently covering the stock, Marketbeat Ratings reports.
Yahoo Web Search
Trending Now
